Emergent BioSolutions (NYSE:EBS) Lowered to Hold Rating by StockNews.com

StockNews.com downgraded shares of Emergent BioSolutions (NYSE:EBS) from a buy rating to a hold rating in a report released on Friday morning.

EBS has been the topic of several other reports. Rodman & Renshaw reiterated a “buy” rating and issued a $16.00 price target on shares of Emergent BioSolutions in a report on Friday, September 13th. Benchmark increased their target price on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th.

Emergent BioSolutions Stock Performance

Shares of NYSE:EBS opened at $8.10 on Friday. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. Emergent BioSolutions has a 12 month low of $1.42 and a 12 month high of $15.10. The company has a market capitalization of $438.89 million, a price-to-earnings ratio of -1.98 and a beta of 1.59. The firm’s 50-day moving average is $9.30 and its 200 day moving average is $8.78.

Institutional Trading of Emergent BioSolutions

Institutional investors and hedge funds have recently modified their holdings of the stock. Meeder Asset Management Inc. bought a new stake in Emergent BioSolutions during the 2nd quarter valued at $41,000. Verus Capital Partners LLC bought a new stake in shares of Emergent BioSolutions in the second quarter valued at about $68,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Emergent BioSolutions in the second quarter valued at about $93,000. Stifel Financial Corp purchased a new stake in Emergent BioSolutions in the third quarter worth about $96,000. Finally, Morse Asset Management Inc bought a new position in Emergent BioSolutions during the 2nd quarter worth about $97,000. Institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.